PDCD1 and neoplasm: The most clinically successful class of checkpoint inhibitor therapies are antibodies targeting the programmed cell death protein 1/programmed-death ligand 1 (PD-1/PD-L1) axis, which have shown benefits to overall survival in multiple tumor types.